Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patients

Abstract Background Vilobelimab, a complement 5a (C5a)-specific monoclonal antibody, reduced mortality in critically ill COVID-19 patients in a phase 3 multicentre, randomized, double-blind, placebo-controlled study. As part of the study, vilobelimab concentrations and C5a levels as well as antidrug...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Endry H. T. Lim, Alexander P. J. Vlaar, Sanne de Bruin, Simon Rückinger, Claus Thielert, Maria Habel, Renfeng Guo, Bruce P. Burnett, James Dickinson, Matthijs C. Brouwer, Niels C. Riedemann, Diederik van de Beek, the PANAMO study group
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	SpringerOpen 2023-06-01
Schriftenreihe:	Intensive Care Medicine Experimental
Schlagworte:	PK Pharmacokinetic C5a Complement Vilobelimab ADA
Online-Zugang:	https://doi.org/10.1186/s40635-023-00520-8
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!